BeiGeneius - Next-generation BTK inhibitors for relapsed/refractory B-cell malignancies: What are the options and how do they compare?

 VIDEO   1:28:45   10/2021

BeiGeneius - Next-generation BTK inhibitors for relapsed/refractory B-cell malignancies: What are the options and how do they compare?

Monday, September 27, 2021 | 17:30–19:00 (CEST)

 

Wojciech Jurczak
Maria Skłodowska-Curie National Research Institute of Oncology, Poland

 

Paolo Ghia
The Vita-Salute San Raffaele University, Italy

 

Federico Pea
University of Bologna, Italy

 

Alessandra Tedeschi
Niguarda Cancer Center, Italy

Rating

Rate this resource